- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PP0176 | Recombinant Protein-Brucella melitensis 17 kd surface antigen (a.a.19 to 131) | Q8YG27 | 100 µg | 1195 | |
PP0177 | Recombinant Protein-Brucella melitensis 26 kDa periplasmic immunogenic protein (a.a.32 to 250) | P0A3U8 | 100 µg | 1195 | |
PP0178 | Recombinant Protein-Brucella melitensis LPSA protein (a.a.35 to 435) | D0B257 | 100 µg | 1195 | |
PP0179 | Recombinant Protein-Brucella melitensis Surface antigen (a.a.61 to 460) | D1F615 | 100 µg | 1195 | |
PP0180 | Recombinant Protein-Brucella melitensis Uncharacterized protein BMEII0376 (a.a.20 to 284) | Q8YD01 | 100 µg | 1195 | |
PP0181 | Recombinant Protein-Brucella melitensis biotype 2 Surface antigen D15 (a.a.30 to 450) | C0RGB1 | 100 µg | 1195 | |
RPP0176 | cDNA-Brucella melitensis 17 kd surface antigen (a.a.19 to 131) | Q8YG27 | 2 µg | 800 | |
RPP0177 | cDNA-Brucella melitensis 26 kDa periplasmic immunogenic protein (a.a.32 to 250) | P0A3U8 | 2 µg | 1090 | |
RPP0178 | cDNA-Brucella melitensis LPSA protein (a.a.35 to 435) | D0B257 | 2 µg | 2000 | |
RPP0179 | cDNA-Brucella melitensis Surface antigen (a.a.61 to 460) | D1F615 | 2 µg | 1995 | |
RPP0180 | cDNA-Brucella melitensis Uncharacterized protein BMEII0376 (a.a.20 to 284) | Q8YD01 | 2 µg | 1320 | |
RPP0181 | cDNA-Brucella melitensis biotype 2 Surface antigen D15 (a.a.30 to 450) | C0RGB1 | 2 µg | 2100 |
Brucella melitensis cDNA and recombinant antigen
Brucella melitensis is a pathogenic bacterium responsible for causing brucellosis in humans and animals. The bacterium possesses several proteins, including 17 kd surface antigen, 26 kDa periplasmic immunogenic protein, LPSA protein, Surface antigen, Uncharacterized protein BMEII0376, and biotype 2 Surface antigen D15. These proteins play a crucial role in the bacterium’s virulence and ability to survive in the host’s body. In this article, we will explore each of these proteins and their respective functions.
17 kd Surface Antigen:
The 17 kd surface antigen is a vital protein that contributes to the virulence of Brucella melitensis. This protein plays a crucial role in the bacterium’s ability to evade the host’s immune system, allowing it to survive in the host’s body. Studies have shown that this protein is responsible for stimulating an immune response in the host, which further contributes to the bacterium’s virulence.
26 kDa Periplasmic Immunogenic Protein:
The 26 kDa periplasmic immunogenic protein is an essential protein found in Brucella melitensis. This protein plays a crucial role in the bacterium’s survival in the host’s body. The protein has also shown potential as a subunit vaccine candidate, as it can stimulate an immune response in the host.
LPSA Protein:
The LPSA protein, or lipopolysaccharide-associated protein, is involved in the formation of the outer membrane of Brucella melitensis. This protein plays a crucial role in the bacterium’s virulence, and it is involved in the bacterium’s ability to cause disease in humans and animals.
Surface Antigen:
The Surface Antigen is another vital protein found in Brucella melitensis. This protein is responsible for the bacterium’s attachment to host cells, which further contributes to its ability to invade host tissues. The protein is also involved in the bacterium’s virulence and plays a crucial role in the bacterium’s survival in the host’s body.
Uncharacterized Protein BMEII0376:
The Uncharacterized Protein BMEII0376 is a protein whose exact function is not yet fully understood. However, studies have shown that this protein is involved in the bacterium’s survival in the host’s body. Further research is needed to determine the precise role of this protein in Brucella melitensis.
Biotype 2 Surface Antigen D15:
The Biotype 2 Surface Antigen D15 is a protein found specifically in biotype 2 of Brucella melitensis. This protein is involved in the bacterium’s virulence and plays a crucial role in the bacterium’s ability to cause disease in humans and animals. The protein is also involved in the bacterium’s survival in the host’s body.
The proteins found in Brucella melitensis play a crucial role in the bacterium’s virulence, survival, and ability to cause disease. Understanding the roles of each of these proteins is vital in developing treatments and vaccines for brucellosis. Further research is needed to explore the functions of uncharacterized proteins like BMEII0376 and to develop new approaches to combating the bacterium’s virulence.
The cDNA (complementary DNA) and recombinant antigens of Brucella melitensis have various applications in the fields of molecular biology and infectious disease, including:
Gene expression analysis: The cDNA can be used as a template to synthesize complementary RNA (cRNA) which can then be used for microarray or RNA sequencing (RNA-seq) analysis to study gene expression patterns in the bacterium under different conditions.
Antimicrobial resistance studies: The cDNA can be used to study the mechanisms of antibiotic resistance in Brucella melitensis, including the identification of genes involved in resistance and the evaluation of the expression of these genes.
Vaccine development: The recombinant antigens of Brucella melitensis can be used to develop subunit vaccines against the bacterium. These antigens can stimulate the immune system to mount a response against the pathogen.
Diagnostics: The cDNA can be used to develop real-time PCR (polymerase chain reaction) assays for the rapid and sensitive detection of Brucella melitensis in clinical specimens, such as blood, synovial fluid, and cerebrospinal fluid.
Serological assays: The recombinant antigens of Brucella melitensis can be used to develop serological assays, such as ELISA (enzyme-linked immunosorbent assay), to detect the presence of antibodies against the bacterium in animal serum. These assays can be used for the diagnosis of Brucella melitensis infections in livestock.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple